Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review

被引:24
|
作者
Szucs, T. . D.
Bramkamp, M.
机构
[1] Univ Zurich, Inst Social & Prevent Med, CH-8001 Zurich, Switzerland
[2] Univ Hosp Zurich, Med Policlin, Dept Internal Med, Zurich, Switzerland
关键词
anticoagulation therapy; atrial fibrillation; cost-effectiveness; stroke; vitamin K antagonists; warfarin;
D O I
10.1111/j.1538-7836.2006.01890.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Atrial fibrillation (AF) increases the risk of ischemic stroke 5-fold and may not only be responsible for as many as 15% of all strokes that occur but also for larger and more disabling strokes than those attributable to other causes which increase the associated costs of care. Anticoagulation with warfarin in the target INR of 2.5 is a major clinical challenge in real-life practice, given that the complex relationship between warfarin dosage and response is readily altered by a variety of factors such as concurrent medications, illnesses, genetic influences, and dietary/lifestyle changes. Consequently, INR values are out of the target range approximately half of the time in real-life studies compared to clinical trial setting. Current anticoagulation therapies are less likely to be cost-effective in routine clinical practice and need improvement. The aim of this review is to discuss the pharmacoeconomic consequences of this management strategy by analysing the optimal treatment option within specific age and risk groups, confirming current guidelines for a health economic perspective and considering the economic impact on health care policy. Methods: An electronic search of the Medline/PubMed database from 1966 to 2005 was performed to identify articles dealing with all pharmacoeconomic aspects of stroke prevention in atrial fibrillation. The following search terms were used: 'atrial fibrillation', 'stroke', 'cost', 'warfarin'. Results: Treatment with warfarin is cost-effective (versus aspirin or no therapy) in patients with AF at moderate-to-high risk of stroke. The cost-effectiveness of anticoagulation therapy is driven by the achieved risk reduction rather than the potential benefits estimated from clinical trials. Failure to maintain optimal anticoagulation places patients at risk of complications, the management of which is a significant cost driver. Conclusion: Improvement could be achieved by optimising physicians and patient's knowledge driven through prevention campaigns by health care policy.
引用
收藏
页码:1180 / 1185
页数:6
相关论文
共 50 条
  • [41] Atrial Fibrillation in American Indians: Comparative Analysis of Characteristics and Anticoagulation Use for Stroke Prevention of Atrial Fibrillation
    Vargas, Juan
    Deora, Kunal
    Yadav, Ritu
    Ashurst, John
    Forbeck, Taylor
    Lowis, Jaron
    Jha, Neha, III
    Peloquin, Sarah
    Ashraf, Hammad
    Nagarakanti, Rangadham
    CIRCULATION, 2024, 150
  • [42] Stroke Prevention in Atrial Fibrillation: an Audit of Symptom to Anticoagulation Treatment Time
    Ward, L.
    Hargroves, D.
    CEREBROVASCULAR DISEASES, 2015, 39 : 244 - 244
  • [43] Anticoagulation for stroke prevention in atrial fibrillation — new concepts, new challenges
    Remmel M.
    Blankenberg S.
    MMW - Fortschritte der Medizin, 2018, 160 (Suppl 3) : 34 - 38
  • [44] Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people
    Vasishta, S
    Toor, F
    Johansen, A
    Hasan, M
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2001, 33 (03) : 219 - 226
  • [45] Atrial fibrillation and anticoagulation in patients with permanent pacemakers: Implications for stroke prevention
    Sparks, PB
    Mond, HG
    Kalman, JM
    Jayaprakash, S
    Lewis, MA
    Grigg, LE
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1998, 21 (06): : 1258 - 1267
  • [46] Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation
    Garcia, David A.
    THROMBOSIS RESEARCH, 2012, 129 (01) : 9 - 16
  • [47] Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
    Zulkifly, Hanis
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2022, 2022
  • [48] Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy - Evidence for under-use of anticoagulation
    Carlsson, J
    Miketic, S
    Dees, G
    Haun, S
    Cuneo, A
    Tebbe, U
    EUROPACE, 2000, 2 (02): : 115 - 118
  • [49] Oral anticoagulation and stroke in atrial fibrillation
    Epstein, EF
    Natarajan, I
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (24): : 2360 - 2361
  • [50] Anticoagulation Therapy for Atrial Fibrillation
    Hylek, Elaine M.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (02): : 147 - 152